Charles River Laboratories Debt to Equity Ratio 2010-2024 | CRL

Current and historical debt to equity ratio values for Charles River Laboratories (CRL) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Charles River Laboratories debt/equity for the three months ending September 30, 2024 was 0.61.
Charles River Laboratories Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2024-09-30 $4.22B $3.79B 1.11
2024-06-30 $4.22B $3.73B 1.13
2024-03-31 $4.51B $3.65B 1.24
2023-12-31 $4.59B $3.60B 1.28
2023-09-30 $4.30B $3.31B 1.30
2023-06-30 $4.52B $3.26B 1.39
2023-03-31 $4.59B $3.11B 1.47
2022-12-31 $4.62B $2.98B 1.55
2022-09-30 $4.75B $2.63B 1.80
2022-06-30 $4.88B $2.65B 1.84
2022-03-31 $4.46B $2.62B 1.71
2021-12-31 $4.49B $2.54B 1.77
2021-09-30 $4.63B $2.43B 1.90
2021-06-30 $4.40B $2.32B 1.89
2021-03-31 $3.62B $2.19B 1.66
2020-12-31 $3.37B $2.12B 1.59
2020-09-30 $3.31B $1.90B 1.74
2020-06-30 $3.48B $1.76B 1.98
2020-03-31 $3.55B $1.66B 2.14
2019-12-31 $3.06B $1.64B 1.87
2019-09-30 $3.05B $1.54B 1.98
2019-06-30 $3.17B $1.46B 2.17
2019-03-31 $2.53B $1.40B 1.80
2018-12-31 $2.54B $1.32B 1.92
2018-09-30 $2.54B $1.26B 2.02
2018-06-30 $2.68B $1.19B 2.26
2018-03-31 $1.86B $1.14B 1.63
2017-12-31 $1.88B $1.05B 1.80
2017-09-30 $1.84B $1.03B 1.80
2017-06-30 $1.81B $0.97B 1.87
2017-03-31 $1.82B $0.88B 2.07
2016-12-31 $1.87B $0.84B 2.23
2016-09-30 $1.82B $0.87B 2.08
2016-06-30 $1.93B $0.84B 2.30
2016-03-31 $1.32B $0.78B 1.68
2015-12-31 $1.33B $0.74B 1.81
2015-09-30 $1.32B $0.71B 1.87
2015-06-30 $1.18B $0.71B 1.67
2015-03-31 $1.18B $0.67B 1.77
2014-12-31 $1.20B $0.68B 1.77
2014-09-30 $1.17B $0.67B 1.73
2014-06-30 $1.19B $0.68B 1.76
2014-03-31 $0.95B $0.70B 1.36
2013-12-31 $0.99B $0.64B 1.54
2013-09-30 $0.98B $0.66B 1.49
2013-06-30 $0.97B $0.65B 1.49
2013-03-31 $0.97B $0.63B 1.54
2012-12-31 $0.98B $0.60B 1.63
2012-09-30 $0.97B $0.60B 1.61
2012-06-30 $0.98B $0.57B 1.74
2012-03-31 $1.00B $0.56B 1.81
2011-12-31 $1.03B $0.53B 1.96
2011-09-30 $1.04B $0.54B 1.93
2011-06-30 $1.12B $0.59B 1.89
2011-03-31 $1.18B $0.56B 2.09
2010-12-31 $1.05B $0.69B 1.52
2010-09-30 $1.04B $1.04B 1.00
2010-06-30 $0.76B $1.39B 0.55
2010-03-31 $0.80B $1.38B 0.58
2009-12-31 $0.83B $1.37B 0.60
2009-09-30 $0.84B $1.35B 0.62
2009-06-30 $0.87B $1.28B 0.68
2009-03-31 $0.87B $1.22B 0.71
Sector Industry Market Cap Revenue
Medical Medical Services $10.011B $4.129B
Charles River Laboratories International, Inc. is a full service, early-stage contract research organization. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research and drug development efforts. The company has a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP. This helps support its clients from target identification through non-clinical development. Charles River also provides a line of products and services to support clients' manufacturing activities. Utilizing the company's broad portfolio of products and services, clients can create a more flexible drug development model, aiming cost reduction, productivity enhancement and increase in speed to market. Charles River currently has three reporting segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Support.
Stock Name Country Market Cap PE Ratio
Elevance Health (ELV) United States $93.361B 11.58
Cencora (COR) United States $48.280B 17.81
DiDi Global (DIDIY) China $22.212B 0.00
Natera (NTRA) United States $22.082B 0.00
ICON (ICLR) Ireland $17.675B 15.74
Viatris (VTRS) United States $15.958B 4.92
Avantor (AVTR) United States $14.143B 21.20
Revvity (RVTY) United States $13.634B 23.68
CochLear (CHEOY) Australia $12.777B 0.00
Solventum (SOLV) United States $12.233B 0.00
BioMerieux (BMXMF) France $11.895B 0.00
Medpace Holdings (MEDP) United States $10.498B 29.58
HealthEquity (HQY) United States $9.104B 49.41
Doximity (DOCS) United States $8.999B 52.97
Sonic Healthcare (SKHHY) Australia $8.862B 0.00
Bausch + Lomb (BLCO) Canada $6.892B 32.08
Life Times (LTH) United States $5.081B 33.63
Organon (OGN) United States $3.935B 3.97
Sotera Health (SHC) United States $3.631B 19.42
BrightSpring Health Services (BTSG) United States $3.265B 69.44
Surgery Partners (SGRY) United States $2.925B 33.35
Concentras Parent (CON) United States $2.789B 0.00
PACS (PACS) United States $2.515B 0.00
Alignment Healthcare (ALHC) United States $2.310B 0.00
Ardent Health Partners (ARDT) United States $2.259B 0.00
Premier (PINC) United States $2.195B 11.42
GeneDx Holdings (WGS) United States $2.162B 0.00
Ryman Healthcare (RYHTY) New Zealand $1.995B 0.00
GoodRx Holdings (GDRX) United States $1.868B 49.00
Teladoc Health (TDOC) United States $1.828B 0.00
Progyny (PGNY) United States $1.315B 26.62
Pediatrix Medical (MD) United States $1.285B 12.57
CareDx (CDNA) United States $1.241B 0.00
Establishment Labs Holdings (ESTA) $1.206B 0.00
AMN Healthcare Services Inc (AMN) United States $0.984B 6.66
Embecta (EMBC) United States $0.797B 5.32
QDM (QDMI) Hong Kong, SAR China $0.790B 20.69
Agilon Health (AGL) United States $0.779B 0.00
SBC Medicals (SBC) United States $0.674B 0.00
InnovAge Holding (INNV) United States $0.662B 0.00
Auna S.A (AUNA) Luxembourg $0.522B 0.00
Sonida Senior Living (SNDA) United States $0.474B 0.00
DocGo (DCGO) United States $0.434B 16.35
Enhabit (EHAB) United States $0.380B 32.87
COMPASS Pathways (CMPS) United Kingdom $0.302B 0.00
ModivCare (MODV) United States $0.254B 13.79
LifeMD (LFMD) United States $0.251B 0.00
Sera Prognostics (SERA) United States $0.221B 0.00
Biodesix (BDSX) United States $0.186B 0.00
Nutex Health (NUTX) United States $0.179B 0.00
Beauty Health (SKIN) United States $0.176B 0.00
MultiPlan (MPLN) United States $0.112B 0.00
So-Young (SY) China $0.086B 16.60
Ascend Wellness Holdings (AAWH) United States $0.085B 0.00
Singular Genomics Systems (OMIC) United States $0.054B 0.00
OncoCyte (OCX) United States $0.046B 0.00
NeueHealth (NEUE) United States $0.041B 1.10
IceCure Medical (ICCM) Israel $0.032B 0.00
Co-Diagnostics (CODX) United States $0.032B 0.00
Pheton Holdings (PTHL) China $0.031B 0.00
NeuroOne Medical Technologies (NMTC) United States $0.021B 0.00
Oncology Institute (TOI) United States $0.012B 0.00
SeaStar Medical Holding (ICU) United States $0.009B 0.00
XWELL (XWEL) United States $0.008B 0.00
Intelligent Bio Solutions (INBS) United States $0.007B 0.00
KindlyMD (KDLY) United States $0.006B 0.00
BioNexus Gene Lab (BGLC) $0.005B 0.00
ISpecimen (ISPC) United States $0.004B 0.00
NewGenIvf Group (NIVF) Thailand $0.002B 0.00
Aclarion (ACON) United States $0.002B 0.00
Cano Health (CANOQ) United States $0.001B 0.00